Samsung Biologics Co Ltd Cash Flow Conversion Efficiency

Latest as of June 2026: 0.075x

Samsung Biologics Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Samsung Biologics Co Ltd (207940) has a cash flow conversion efficiency ratio of 0.075x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩624.80 Billion ≈ $423.42 Million USD) by net assets (₩8.36 Trillion ≈ $5.67 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Samsung Biologics Co Ltd (2014–2025)

Cash flow conversion efficiency of Samsung Biologics Co Ltd from 2014 to 2025. This chart illustrates how Samsung Biologics Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 207940 share price today for real-time trading data and today's change.

Samsung Biologics Co Ltd Cash Flow Conversion Ratio Explained

Samsung Biologics Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Samsung Biologics Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Samsung Biologics Co Ltd ranked by their cash flow conversion efficiency. Also see 207940 company net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
SIEMENS HEALTH ADR/050 F:SHL1	0.027x
Waste Connections Inc TO:WCN	0.090x
Polski Koncern Naftowy ORLEN SA WAR:PKN	0.089x
Vistra Energy Corp NYSE:VST	0.281x
State Street Corp NYSE:STT	-0.082x
Nike Inc NYSE:NKE	0.031x
Hangzhou Hikvision Digital Technology Co Ltd SHE:002415	0.089x
COMPASS GROUP F:XGR	N/A

Annual Cash Flow Conversion Efficiency for Samsung Biologics Co Ltd (2014–2025)

The table below shows the annual cash flow conversion efficiency of Samsung Biologics Co Ltd from 2014 to 2025. Review Samsung Biologics Co Ltd (207940) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩7.45 Trillion ≈ $5.05 Billion	₩2.25 Trillion ≈ $1.52 Billion	0.302x	+98.26%
2024-12-31	₩10.90 Trillion ≈ $7.39 Billion	₩1.66 Trillion ≈ $1.12 Billion	0.152x	-10.23%
2023-12-31	₩9.83 Trillion ≈ $6.66 Billion	₩1.67 Trillion ≈ $1.13 Billion	0.169x	+59.79%
2022-12-31	₩8.98 Trillion ≈ $6.09 Billion	₩953.05 Billion ≈ $645.87 Million	0.106x	+16.46%
2021-12-31	₩4.99 Trillion ≈ $3.38 Billion	₩454.60 Billion ≈ $308.07 Million	0.091x	+107.27%
2020-12-31	₩4.60 Trillion ≈ $3.12 Billion	₩202.09 Billion ≈ $136.95 Million	0.044x	+1784.58%
2019-12-31	₩4.35 Trillion ≈ $2.95 Billion	₩10.15 Billion ≈ $6.88 Million	0.002x	+129.35%
2018-12-31	₩4.16 Trillion ≈ $2.82 Billion	₩-33.02 Billion ≈ $-22.38 Million	-0.008x	-121.09%
2017-12-31	₩3.98 Trillion ≈ $2.69 Billion	₩149.82 Billion ≈ $101.53 Million	0.038x	+345.46%
2016-12-31	₩4.08 Trillion ≈ $2.77 Billion	₩-62.66 Billion ≈ $-42.46 Million	-0.015x	+83.96%
2015-12-31	₩2.77 Trillion ≈ $1.88 Billion	₩-265.51 Billion ≈ $-179.93 Million	-0.096x	+44.27%
2014-12-31	₩630.73 Billion ≈ $427.44 Million	₩-108.30 Billion ≈ $-73.39 Million	-0.172x	--

About Samsung Biologics Co Ltd

KO:207940 Korea Biotechnology

Market Cap

$46.65 Billion

₩68.83 Trillion KRW

Market Cap Rank

#574 Global

#7 in Korea

Share Price

₩1487000.00

Change (1 day)

+8.86%

52-Week Range

₩1000000.00 - ₩1609000.00

All Time High

₩1609000.00